Lantern Pharma Inc.
Tremor tracks 2 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
None right now.
Trials
- LTRNLantern Pharma Inc.0Calm
A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
Signing up patientsPhase 290 patientsMain results: Dec 2026 - LTRNLantern Pharma Inc.0Calm
Study of LP-184 in Patients With Advanced Solid Tumors
Running, no new patientsPhase 1/264 patientsMain results: Jul 28, 2026
Key executives leaving
From the last 12 months of the company's SEC reports.
None found.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
0 sales (0 not pre-planned) · 2 purchases
- Schalop Lee TroyBoard member · May 12, 2026Bought 48,544 sharesabout $100 thousand ·
- KEYSER D JEFFREYBoard member · May 12, 2026Bought 48,544 sharesabout $100 thousand ·
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.
- Warning about being removed from the stock exchangeNews report (8-K)Oct 1, 2026
- Signed a major agreementNews report (8-K)Sep 30, 2026
- New shares being soldNew shares being sold (424B5)Sep 30, 2026
- Shared information with investorsNews report (8-K)Sep 24, 2026
- Shared information with investorsNews report (8-K)Sep 23, 2026
Money left
Coming soon: how many months of cash the company has, from its quarterly reports.